CASI Global Controller discloses stock option holdings

CASI Pharmaceuticals, Inc. filed an initial ownership report showing that Global Controller Qian Kun holds several stock option awards on the company’s ordinary shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. filed an initial ownership report showing that Global Controller Qian Kun holds several stock option awards on the company’s ordinary shares. The options cover different blocks of shares with exercise prices of $1.93, $2.67, and $5.78 per share and expire between 2032 and 2034. Footnotes state that the options are fully vested and exercisable as of the reporting date, and that some are performance based and become exercisable upon achievement of a performance target.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Qian Kun

Role Global Controller

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 75,000 contracts (Direct)

Footnotes (2)

F1. The options are fully vested and exercisable as of the date of this form.
F2. Performance based options exercisable upon achievement of performance target.

Key Figures

Option grant underlying shares: 8,000 shares Option grant underlying shares: 13,333 shares Option grant underlying shares: 6,667 shares +3 more

6 metrics

Option grant underlying shares 8,000 shares Ordinary shares at $1.93 exercise price expiring March 20, 2032

Option grant underlying shares 13,333 shares Ordinary shares at $1.93 exercise price expiring May 12, 2033

Option grant underlying shares 6,667 shares Ordinary shares at $1.93 exercise price expiring May 12, 2033

Option grant underlying shares 3,000 shares Ordinary shares at $2.67 exercise price expiring June 18, 2034

Large option grant underlying shares 30,000 shares Ordinary shares at $5.78 exercise price expiring November 6, 2034

Additional option grant underlying shares 5,000 shares Ordinary shares at $5.78 exercise price expiring November 6, 2034

Key Terms

Option (right to buy), Global Controller, Performance based options, exercise price, +1 more

5 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Global Controller financial

"officer_title: "Global Controller""

Performance based options financial

"Performance based options exercisable upon achievement of performance target."

exercise price financial

"conversion_or_exercise_price: "1.9300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2034-11-06T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CASI (CASIF) Form 3 filing for Qian Kun show?

The Form 3 shows Global Controller Qian Kun’s existing stock option holdings in CASI Pharmaceuticals. It lists multiple options on ordinary shares with exercise prices of $1.93, $2.67, and $5.78 and expirations between 2032 and 2034.

How many CASI Pharmaceuticals shares are covered by Qian Kun’s options?

The filing lists several option positions over ordinary shares, including 8,000, 13,333, 6,667, 3,000 blocks and larger grants of 30,000 and 5,000 shares. Each line represents a separate option award with its own price and expiration date.

What are the exercise prices of Qian Kun’s CASI stock options?

The options disclosed carry exercise prices of $1.93, $2.67, and $5.78 per ordinary share. Each exercise price applies to specific grants, which also have different expiration dates extending from 2032 through 2034.

When do Qian Kun’s CASI Pharmaceuticals options expire?

The disclosed options expire on several future dates between 2032 and 2034. Specific expirations include March 20, 2032, May 12, 2033, June 18, 2034, and November 6, 2034, depending on the individual option grant.

Are Qian Kun’s CASI stock options already vested and exercisable?

A footnote states that the options are fully vested and exercisable as of the Form 3 date. Another footnote explains that certain performance based options become exercisable only upon achievement of a specified performance target, adding a performance condition to those particular grants.

Does the CASI Form 3 show any recent insider buying or selling by Qian Kun?

The Form 3 is an initial ownership statement and lists existing option holdings rather than new market trades. The transaction summary shows no recorded buy or sell transactions, only holding entries for previously granted stock options on CASI ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/13/2026 - 04:30 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Qian Kun

(Last)

(First)

(Middle)

1701, CHINA CENTRAL OFFICE TOWER 1

NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT

(Street)

BEIJING

100025

(City)

(State)

(Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Global Controller

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)	⁽¹⁾	03/20/2032	Ordinary Share	8,000	$1.93	D
Option (right to buy)	⁽¹⁾	05/12/2033	Ordinary Share	13,333	$1.93	D
Option (right to buy)	05/12/2026	05/12/2033	Ordinary Share	6,667	$1.93	D
Option (right to buy)	⁽¹⁾	06/18/2034	Ordinary Share	3,000	$2.67	D
Option (right to buy)	06/18/2026	06/18/2034	Ordinary Share	3,000	$2.67	D
Option (right to buy)	06/18/2027	06/18/2034	Ordinary Share	3,000	$2.67	D
Option (right to buy)	06/18/2028	06/18/2034	Ordinary Share	3,000	$2.67	D
Option (right to buy)	⁽¹⁾	11/06/2034	Ordinary Share	30,000	$5.78	D
Option (right to buy)	⁽²⁾	11/06/2034	Ordinary Share	5,000	$5.78	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

2. Performance based options exercisable upon achievement of performance target.

	/s/ Kun Qian	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR